FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize ...
The approval gives Freenome its first commercial product and lets Abbott market the test to average-risk adults who skip stool-based screening.
8 Articles
8 Articles
As Minority Health Awareness Month Ends, New Colorectal Cancer Screening Guidelines Focus On Expanding Patient Choice
July’s National Minority Mental Health Awareness Month shines a light on barriers that can prevent individuals from accessing the care they need. While much of the conversation centers on mental health services, many of those same obstacles can influence participation in preventive healthcare, including cancer screening. The reality is reflected in a recent update to […]
Freenome secures FDA nod for blood-based colorectal cancer test
Abbott will market Freenome’s SimpleScreen CRC test in the U.S., alongside its Cologuard stool test. SimpleScreen will compete with Guardant Health’s Shield blood test for colorectal cancer screening.
FDA approves Freenome's blood test for colorectal cancer screening ...
FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
Freenome is a biotech company focused on developing blood tests to detect cancer early and make screening accessible for everyone.- Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for screening
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
